Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287891 | 0.89 | MAPT (0.54) | HRH3MAPTALDH1A1LMNAHDAC1 | |
| SCHEMBL18229441 | 0.82 | HRH3 (0.65) | HRH3MAPTALDH1A1LMNAHDAC1 | |
| SCHEMBL6287895 | 0.81 | HRH3 (0.53) | HRH3MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6287783 | 0.80 | HDAC8 (0.61) | MAPTLMNASMN1; SMN2HDAC1HTT | |
| SCHEMBL6287685 | 0.80 | HDAC1 (0.52) | HRH3MAPTALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL31218207 | 0.80 | HRH3 (0.67) | HRH3MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7807900 | 0.80 | HRH3 (0.67) | HRH3MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL27333111 | 0.79 | HRH3 (0.67) | HRH3MAPTALDH1A1LMNAHDAC1 | |
| SCHEMBL29411993 | 0.79 | LMNA (0.65) | MAPTALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL468296 | 0.79 | LMNA (0.65) | MAPTALDH1A1LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | HRH3 2351/4885MAPT 4866/4885ALDH1A1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.